Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Lublin

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Neurology|October 24, 2024
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?Gabriel Bsteh, Nik Krajnc, Patrick Altmann, et al.
International Journal of MS Care|December 22, 2016
CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific CircumstancesScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
International Journal of MS Care|March 1, 2017
A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and BeyondScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
Multiple Sclerosis and Related Disorders|June 2, 2021
Dietary factors and MRI metrics in early Multiple SclerosisI B Katz Sand, Kathryn C Fitzgerald, Yian Gu, et al.
Journal of Neurology|March 25, 2026
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension studyXavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, et al.
Neurology|July 12, 2020
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosisGavin Giovannoni, Volker Knappertz, Joshua R Steinerman, et al.
Multiple Sclerosis and Related Disorders|September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapsesSamantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 25, 2019
Dissociable cognitive patterns related to depression and anxiety in multiple sclerosisVictoria M Leavitt, Rachel Brandstadter, Michelle Fabian, et al.
Annals of Neurology|September 7, 2010
Considerations on discontinuing natalizumab for the treatment of multiple sclerosisJoseph R Berger, Diego Centonze, Giancarlo Comi, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Neurology|October 24, 2024
Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?Gabriel Bsteh, Nik Krajnc, Patrick Altmann, et al.
International Journal of MS Care|December 22, 2016
CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific CircumstancesScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
International Journal of MS Care|March 1, 2017
A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and BeyondScott D Newsome, Philip J Aliotta, Jacquelyn Bainbridge, et al.
Multiple Sclerosis and Related Disorders|June 2, 2021
Dietary factors and MRI metrics in early Multiple SclerosisI B Katz Sand, Kathryn C Fitzgerald, Yian Gu, et al.
Journal of Neurology|March 25, 2026
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension studyXavier Montalban, Reinhard Hohlfeld, Carlo Pozzilli, et al.
Neurology|July 12, 2020
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosisGavin Giovannoni, Volker Knappertz, Joshua R Steinerman, et al.
Multiple Sclerosis and Related Disorders|September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapsesSamantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 25, 2019
Dissociable cognitive patterns related to depression and anxiety in multiple sclerosisVictoria M Leavitt, Rachel Brandstadter, Michelle Fabian, et al.
Annals of Neurology|September 7, 2010
Considerations on discontinuing natalizumab for the treatment of multiple sclerosisJoseph R Berger, Diego Centonze, Giancarlo Comi, et al.
Pageof 10